JP5303728B2 - Ｏａｓ１遺伝子内の突然変異 - Google Patents

Ｏａｓ１遺伝子内の突然変異 Download PDF

Info

Publication number
JP5303728B2
JP5303728B2 JP2008510166A JP2008510166A JP5303728B2 JP 5303728 B2 JP5303728 B2 JP 5303728B2 JP 2008510166 A JP2008510166 A JP 2008510166A JP 2008510166 A JP2008510166 A JP 2008510166A JP 5303728 B2 JP5303728 B2 JP 5303728B2
Authority
JP
Japan
Prior art keywords
polypeptide
present
oas1
polypeptides
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008510166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009504135A5 (enExample
JP2009504135A (ja
Inventor
ショーン ピー． イアドナト，
チャールズ エル． マグネス，
クリスティナ エー． シェーラー，
ピー． キャンピオン フェリン，
トーリー ハーゲン，
エイミー オルソン，
Original Assignee
キネタ・トウー・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キネタ・トウー・エルエルシー filed Critical キネタ・トウー・エルエルシー
Publication of JP2009504135A publication Critical patent/JP2009504135A/ja
Publication of JP2009504135A5 publication Critical patent/JP2009504135A5/ja
Application granted granted Critical
Publication of JP5303728B2 publication Critical patent/JP5303728B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008510166A 2005-05-04 2006-05-03 Ｏａｓ１遺伝子内の突然変異 Expired - Fee Related JP5303728B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67768005P 2005-05-04 2005-05-04
US60/677,680 2005-05-04
PCT/US2006/016983 WO2006119363A2 (en) 2005-05-04 2006-05-03 Mutations in oas1 genes

Publications (3)

Publication Number Publication Date
JP2009504135A JP2009504135A (ja) 2009-02-05
JP2009504135A5 JP2009504135A5 (enExample) 2011-05-12
JP5303728B2 true JP5303728B2 (ja) 2013-10-02

Family

ID=37113984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008510166A Expired - Fee Related JP5303728B2 (ja) 2005-05-04 2006-05-03 Ｏａｓ１遺伝子内の突然変異

Country Status (19)

Country Link
US (4) US20060275802A1 (enExample)
EP (4) EP1877550A2 (enExample)
JP (1) JP5303728B2 (enExample)
KR (3) KR101476844B1 (enExample)
CN (2) CN103642898A (enExample)
AU (1) AU2006242152B2 (enExample)
BR (1) BRPI0611454A2 (enExample)
CA (1) CA2607575A1 (enExample)
HK (1) HK1209454A1 (enExample)
IL (1) IL187079A (enExample)
MX (1) MX2007013765A (enExample)
NO (1) NO20076126L (enExample)
NZ (1) NZ563785A (enExample)
PH (1) PH12014500829A1 (enExample)
RU (2) RU2465328C2 (enExample)
SG (2) SG175656A1 (enExample)
UA (1) UA95446C2 (enExample)
WO (1) WO2006119363A2 (enExample)
ZA (1) ZA200710521B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007529199A (ja) 2003-10-23 2007-10-25 イルミジェン バイオサイエンシーズ， インコーポレイテッド ウイルス感染に対する抵抗性に関連する遺伝子である、ｏａｓ１における変異の検出
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
AU2007321877B2 (en) * 2006-08-01 2011-11-03 Kineta Two, Llc Pharmaceutical manufacturing methods
US20120088681A1 (en) * 2010-02-05 2012-04-12 The Translational Genomics Research Institute Methods and kits used in classifying adrenocortical carcinoma
CN103536900B (zh) * 2012-07-16 2017-06-16 江苏豪森药业集团有限公司 含有促红细胞生成素模拟肽的药物组合物
KR102036532B1 (ko) * 2015-04-09 2019-10-25 아이에스피 인베스트먼츠 엘엘씨 오염으로부터 피부를 보호하고 피부 재생을 개선하기 위한 화장품 트리트먼트 방법
CN106483282B (zh) * 2016-09-29 2018-08-31 北京世纪沃德生物科技有限公司 一种抗原稳定剂及其制备方法与应用
WO2020041500A1 (en) * 2018-08-21 2020-02-27 Georgia State University Research Foundation, Inc. Treatment of flavivirus infections in humans using mus musculus resistant 2'-5' oligoadenylate synthetase 1b
US20230083751A1 (en) * 2019-12-30 2023-03-16 Nanjing GenScript Biotech Co., Ltd. Method For Constructing Gene Mutation Library
CN114409744B (zh) * 2022-03-29 2022-10-04 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用
WO2023245177A2 (en) * 2022-06-17 2023-12-21 The University Of Chicago Targeted nanomedicine for treating lung disorders

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863873A (en) * 1980-01-14 1989-09-05 Esa, Inc. Method for biological testing and/or developing pharmaceuticals for treatment of disorders
JPS60222842A (ja) 1984-04-19 1985-11-07 Fuji Photo Film Co Ltd ハロゲン化銀写真乳剤およびその製造方法
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
DK0452457T3 (da) 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
DE4039415A1 (de) * 1990-02-03 1991-08-08 Boehringer Mannheim Gmbh Verfahren zur herstellung rekombinanter proteine ohne n-terminalen methioninrest
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5266459A (en) * 1992-02-24 1993-11-30 The Scripps Research Institute Gaucher's disease: detection of a new mutation in intron 2 of the glucocerebrosidase gene
DE4208916A1 (de) * 1992-03-20 1993-09-23 Akzo Nv Polyesterfaser und verfahren zu deren herstellung
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5915378A (en) 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5866781A (en) 1993-03-08 1999-02-02 The Cleveland Clinic Foundation Antiviral transgenic plants, vectors, cells and methods
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
US5597709A (en) * 1994-01-27 1997-01-28 Human Genome Sciences, Inc. Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
EP0753992A4 (en) 1994-02-18 1998-02-04 Cleveland Clinic Foundation ANTIVIRAL TRANSGENIC PLANTS, VECTORS, CELLS AND METHODS
KR100419037B1 (ko) 1994-03-07 2004-06-12 넥타르 테라퓨틱스 폐를통한인슐린의전달방법및그조성물
US5597696A (en) 1994-07-18 1997-01-28 Becton Dickinson And Company Covalent cyanine dye oligonucleotide conjugates
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5514758A (en) 1994-09-30 1996-05-07 The Goodyear Tire & Rubber Company Process for making latex for high performance masking tape
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5480640A (en) 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
US5976574A (en) 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
US5765887A (en) * 1997-01-07 1998-06-16 P Ii Inc Apparatus and method for searching pockets and crevices
US5993738A (en) * 1997-05-13 1999-11-30 Universal Air Technology Electrostatic photocatalytic air disinfection
US5855564A (en) 1997-08-20 1999-01-05 Aradigm Corporation Aerosol extrusion mechanism
WO1999013075A2 (en) 1997-09-08 1999-03-18 Princeton University Human genes regulated by human cytomegalovirus and interferon
FR2770300B1 (fr) 1997-10-27 1999-12-31 Vincent Patrice Chritin Dispositif pour la mesure de la vitesse d'un fluide et pour la mesure des flux de particules solides ou liquides dans les fluides ou le vide
US20030044783A1 (en) * 2000-03-09 2003-03-06 Williams Lewis T. Human genes and gene expression products
CA2291889A1 (en) * 1998-03-30 1999-10-07 Esa, Inc. Methodology for predicting and/or diagnosing disease
US5958773A (en) 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
US20010034023A1 (en) * 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
US20030165921A1 (en) * 2000-02-03 2003-09-04 Tang Y. Tom Novel nucleic acids and polypeptides
AU2001245280A1 (en) 2000-03-07 2001-09-17 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001251613A1 (en) 2000-04-14 2001-10-30 Millennum Pharmaceuticals, Inc. Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
FR2823224B1 (fr) 2001-04-04 2003-10-31 Pasteur Institut Utilisation de genes oas impliques dans la sensibilite/resistance a l'infection par les flaviviridae pour le criblage de molecules antivirales
DE10122206A1 (de) 2001-05-08 2002-11-28 Switch Biotech Ag Verwendung von Polypeptiden oder diese kodierende NukleInsäuren einer 2'-5'- Oligoadenylate Synthetase und/oder RNAseL zur Diagnose, Prävention oder Behandlung von Hauterkrankungen oder Wundheilung sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
AU2002341207A1 (en) 2001-05-08 2002-11-18 Switch Biotech Ag Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing
US6818420B2 (en) * 2002-02-27 2004-11-16 Biosource International, Inc. Methods of using FET labeled oligonucleotides that include a 3′-5′ exonuclease resistant quencher domain and compositions for practicing the same
GB0208928D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Methods
AU2003225281A1 (en) * 2002-04-30 2003-11-17 University Of South Florida Materials and methods for prevention and treatment of rna viral diseases
JP2006502738A (ja) * 2002-05-17 2006-01-26 ベイラー カレッジ オブ メディスン オリゴアデニレートシンテターゼ様遺伝子の同定
AU2003248723A1 (en) 2002-06-19 2004-01-06 Georgia State University Research Foundation, Inc. Compositions and methods for viral resistance genes
JP2007529199A (ja) 2003-10-23 2007-10-25 イルミジェン バイオサイエンシーズ， インコーポレイテッド ウイルス感染に対する抵抗性に関連する遺伝子である、ｏａｓ１における変異の検出
US20050191649A1 (en) 2003-10-23 2005-09-01 Illumigen Biosciences, Inc. Detection of mutations in a gene associated with resistance to viral infection, OAS1
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1

Also Published As

Publication number Publication date
NO20076126L (no) 2008-01-30
SG175656A1 (en) 2011-11-28
KR101476844B1 (ko) 2015-01-02
KR20130084323A (ko) 2013-07-24
US20090291074A1 (en) 2009-11-26
US8951768B2 (en) 2015-02-10
RU2465328C2 (ru) 2012-10-27
IL187079A0 (en) 2008-02-09
IL187079A (en) 2015-06-30
KR20080011423A (ko) 2008-02-04
RU2012132651A (ru) 2014-02-10
CN101203604A (zh) 2008-06-18
UA95446C2 (ru) 2011-08-10
MX2007013765A (es) 2008-01-29
PH12014500829A1 (en) 2016-01-18
AU2006242152B2 (en) 2011-11-03
AU2006242152A1 (en) 2006-11-09
SG10201502945PA (en) 2015-05-28
EP2314675A3 (en) 2011-09-07
US9163222B2 (en) 2015-10-20
CA2607575A1 (en) 2006-11-09
WO2006119363A2 (en) 2006-11-09
CN103642898A (zh) 2014-03-19
EP2295552A3 (en) 2011-07-06
EP2314675A2 (en) 2011-04-27
ZA200710521B (en) 2008-11-26
US20120070424A1 (en) 2012-03-22
US8030046B2 (en) 2011-10-04
EP2860246A1 (en) 2015-04-15
NZ563785A (en) 2011-02-25
RU2007144986A (ru) 2009-06-10
EP2314675B1 (en) 2015-04-08
WO2006119363A3 (en) 2007-05-31
EP2295552A2 (en) 2011-03-16
EP1877550A2 (en) 2008-01-16
US20060275802A1 (en) 2006-12-07
US20130142773A1 (en) 2013-06-06
JP2009504135A (ja) 2009-02-05
HK1209454A1 (en) 2016-04-01
BRPI0611454A2 (pt) 2010-09-08
KR20140109510A (ko) 2014-09-15

Similar Documents

Publication Publication Date Title
US8951768B2 (en) Mutations in OAS1 genes
US8859251B2 (en) Oligoadenylate synthetase (OAS)
JP2018161129A (ja) 核酸増幅方法
HK1156346A (en) Mutation in oas1 genes
HK1155490A (en) Mutations in oas1 genes
HK1120553A (en) Mutations in oas1 genes
JP2021006061A (ja) Ｐｃｒ方法
JP6493209B2 (ja) 核酸増幅法

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20081017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121228

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130226

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130508

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130514

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130529

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130531

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees